Tumor-host interaction: Analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas

Human Pathology

Volumn 28, Issue 3, 1997, Pages 321-331

  Merogi, Athir J ^a   Marrogi, Aizen J ^a   Ramesh, Rajagopal ^a   Robinson, William R ^a   Fermin, Cesar D ^a   Freeman, Scott M ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunohistochemistry; ovarian cancer; PCR; tumor infiltrating lymphocytes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HOST PARASITE INTERACTION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; OVARY CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 0031056830     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90131-3     Document Type: Article

References (58)

1. Holmes EC: Immunology of tumor infiltrating lymphocytes. Ann Surg 20:58-63, 1985
2. Balch CM, Riley LB, Bae YJ, et al: Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125:200-205, 1990
3. Slamon DJ, Godolphin W, Joncs LA, et al: Studies of the HER 2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712, 1989
4. Peoples GE, Yoshino I, Douville CC, et al: TCR V. beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. J Immunol 152:4993-4999, 1994
5. Peoples GE, Davey MP, Goedegebuure P, et al: T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 151:5472-5480, 1993
6. Peoples GE, Goedegebuure PS, Smith R, et al: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 92:432-436, 1995
7. Muul LM, Spiess PJ, Director EP, et al: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989-995, 1987
8. Moy PM, Holmes EC, Golub SH: Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 45:57-60, 1985
9. Miescher S, Whiteside TL, Carrel S, et al: Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899-1907, 1986
10. O'Mahony AM, O'Sullivan GC, O'Connell J, et al: An immune supressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 151:4847-4856, 1993
11. Guenther AG, Abrams JS, Nanus DM, et al: Interleukin-10 production by human carcinoma cell lines and its relation to interleukin-6 expression. Int J Cancer 55:96-101, 1993
12. Bartlett JM, Rabias GJ, Scott WN, et al: Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells. Br J Cancer 65:655-660, 1992
13. Ralph P, Nakoinz I, Sampson-Johannes A, et al: IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 148:808-814, 1992
14. de Waal Malefyt R, Yssel H, de Vries JE: Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells: Specific inhibition of IL-2 production and proliferation. J Immunol 150:4754-4765, 1993
15. Fiorentino D, Zlotnik A, Mosmann T, et al: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822, 1991
16. Siepl C, Bodmer S, Frei K, et al: The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor. Eur J Immunol 18:593-600, 1988
17. Ruegemer JJ, Ho SN, Augustine JA, et al: Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol 144:1767-1776, 1990
18. Beverley P: Tumor immunology, in Roitt IM, Brostoff J, Male DK (eds): Immunology (ed 3). St Louis, MO, Mosby, 1993, pp 17.1-17.12
19. Pisa P, Halapi E, Pisa KP, et al: Selective expression of IL-10, interferon γ, and granulocyte-macrophage stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A 89:7708-7712, 1992
20. Vitolo D, Zerbe T, Kanbour A, et al: Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer 51:573-580, 1992
21. 1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. Int J Cancer 52:766-770, 1992
22. Vitolo D, Kanbour A, Johnson JT, et al: In situ hybridization for cytokine gene transcripts in solid tumor microenvironment. Eur J Cancer 29A:371-377, 1993
23. American Joint Commitee on Clinical Cancer: Manual for Staging of Cancer (ed 3). 1988
24. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 162:156-159, 1987
25. Derynch R, Jarrett JA, Chen EY, et al: Human transforming growth factor-b complementary DNA sequence and expression in normal and transformed cells. Nature 316:701-705, 1985
26. Vieira P, de Waal-Malefyt R, Dang MN, et al: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 88:1172-1176, 1991
27. Devos R, Cheroutre H, Taya Y, et al: Molecular cloning of human immuneinterferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res 10:2487-2501, 1982
28. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503, 1975
29. Hus DM, Raine L, Fanger H: Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase technique. J Histochem Cytochem 9:577, 1981
30. Mandell GL, Fisher RI, Bostick F, et al: Ovarian cancer: A solid tumor with evidence of normal cellular immune function but abnormal B cell function. Am J Med 66:621-624, 1979
31. Onsrud M: Immunosuppressive effects of peritoneal fluids from ovarian cancer patients. Gynecol Oncol 23:316-322, 1986
32. Lichtenstein AK, Berek J, Zighelboim J: Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer. Natl Cancer Inst 74:349-355, 1985
33. Wolff JP, de Oliveira CF: Lymphocytes in patients with ovar-ian cancer. Obstet Gynecol 45:656-658, 1975
34. Heo DS, Whiteside TL, Kanbour A, et al: Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocyte infiltrating human ovarian tumors. J Immunol 140:4042-4049, 1988
35. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321, 1986
36. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
37. Stewart JA, Belinson JL, Moore AL, et al: Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50:6302-6310, 1990
38. Steis RG, Urba WJ, VanderMolen LA, et al: Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8:1618-1629, 1990
39. Urba WJ, Clark JW, Steis RG, et al: Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intraabdominal cancer: Immunologic considerations. J Natl Cancer Inst 81:602-611, 1989
40. Wu S, Rodabaugh K, Martinez-Maza O, et al: Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol 166:997-1007, 1992
41. Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555, 1991
42. Bogdan C, Nathan C: Modulation of macrophage function by transforming growth factor-beta, interleukin-4, and interleukin-10. Ann NY Acad Sci 685:713-739, 1993
43. Wanidworanun C, Strober W: Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 51:6853-6861, 1993
44. Ralph P, Nakoinz I, Sampson-Johannes A, et al: IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 148:808-814, 1992
45. Wahl SM, Hunt DA, Wong HL, et al: Transforming growth factor-beta is a potent immunosuppressive agent that inhibits TL-1-dependent lymphocyte proliferation. J Immunol 140:3026-3032, 1988
46. de Waal MR, Yssel H, deVries JE: Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells: Specific inhibition of IL-2 production and proliferation. J Immunol 150:4754-4765, 1993
47. Fiorentino DF, Zlotnik A, Mosmann TR, et al: IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822, 1991
48. Cimoli G, Russo P, Billi G, et al: Human granulocyte-macrophage colony-stimulating factor is a growth factor active on human ovarian cancer cells. Jpn J Cancer Res 82:1196-1198, 1991
49. Moore SC, Theus SA, Barnett JB, et al: Cytokine regulation of bone marrow natural suppressor cell activity in the suppression of lymphocyte function. Cell Immunol 14:398-408, 1992
50. Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1798-1801, 1992
51. Pietenpol JA, Holt JT, Stein RW, et al: Transforming growth factor beta 1 suppression of c-myc gene transcription: Role in inhibition of keratinocyte proliferation. Proc Nad Acad Sci U S A 87:3758-3762, 1990
52. Laiho M, DeCaprio JA, Ludlow JW, et al: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 62:175-185, 1990
53. Smyth MJ, Strobl SL, Young HA, et al: Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T-lymphocytes: Inhibition by transforming growth factor-beta. J Immunol 46:3289-3297, 1991
54. Dubois CM, Ruscetti FW, Palaszynski EW, et al: Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: Proposed mechanism of inhibition of IL-1 action. J Exp Med 172:737-744, 1990
55. Harvey AK, Hrubey PS, Chandrasekhar S: Transforming growth factor-beta inhibition of interleukin-1 activity involves downregulation of interleukin-1 receptors on chondrocytes. Exp Cell Res 195:376-385, 1991
56. Turner M, Chantry D, Katsikis P, et al: Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. Eur J Immunol 21:1635-1639, 1991
57. Dripps DJ, Brandhuber BJ, Thompson RC, et al: Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 266:10331-10336, 1991
58. Brandes ME, Allen JB, Ogawa Y, et al: Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 87:1108-1113, 1991